HER2 testing and clinical decision making in gastroesophageal adenocarcinoma guideline from the College of American Pathologists, American Society for clinical Pathology, and American Society of Clinical Oncology

American Journal of Clinical Pathology

Volumn 146, Issue 6, 2016, Pages 647-669

  Bartley, Angela N ^a   Washington, Mary Kay ^b   Ventura, Christina B ^c   Ismaila, Nofisat ^d   Colasacco, Carol ^c   Al Benson, B ^e   Carrato, Alfredo ^f   Gulley, Margaret L ^g   Jain, Dhanpat ^h   Kakar, Sanjay ⁱ   Mackay, Helen J ^j   Streutker, Catherine ^k   Tang, Laura ^l   Troxell, Megan ^m   Ajani, Jaffer A ⁿ  

^a ST JOSEPH MERCY HOSPITAL   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c North Carolina   (United States)

^d AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF TORONTO   (Canada)

^k ST MICHAEL'S HOSPITAL   (Canada)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF TEXAS   (United States)

more..

Author keywords

Gastroesophageal adenocarcinoma; Guidelines; HER2 testing

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN;

CANCER PATIENT; CANCER PROGNOSIS; CLINICAL DECISION MAKING; ESOPHAGEAL ADENOCARCINOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROESOPHAGEAL JUNCTION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; ONCOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STOMACH ADENOCARCINOMA; ADENOCARCINOMA; ESOPHAGEAL NEOPLASMS; GENETIC SCREENING; GENETICS; PATHOLOGY; STOMACH NEOPLASMS; UNITED STATES;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CLINICAL DECISION-MAKING; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; GENETIC TESTING; HUMANS; MEDICAL ONCOLOGY; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; UNITED STATES;

EID: 85014096639     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1093/AJCP/AQW206     Document Type: Review

References (131)

1. National Cancer Institute. Cancer types. http://www.can cer.gov/types. Accessed July 8, 2016.
2. World Cancer Research Fund International. Cancer facts & figures: worldwide data. http://www.wcrf.org/int/cancerfactsfigures/worldwide-data. Accessed June 28, 2016.
3. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697.
4. Akiyama T, Sudo C, Ogawara H, et al. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 1986;232:1644-1646.
5. Liu L, Wu N, Li J. Novel targeted agents for gastric cancer. J Hematol Oncol. 2012;5:31.
6. Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16:273-278.
7. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523-1529.
8. Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18:476-484.
9. Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol. 2011;18:53-59.
10. Ieni A, Barresi V, Giuffre G, et al. HER2 status in advanced gastric carcinoma: a retrospective multicentric analysis from Sicily. Oncol Lett. 2013;6:1591-1594.
11. Ajani JA, D'Amico TA, Almhanna K, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Gastric Cancer, version 3.2015. National Comprehensive Cancer Network. https://www.nccn.org. Accessed June 28, 2016.
12. Pirrelli M, Caruso ML, Di Maggio M, et al. Are biopsy specimens predictive of HER2 status in gastric cancer patients? Dig Dis Sci. 2013;58:397-404.
13. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797-805.
14. Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014;17:1-12.
15. Ajani JA, D'Amico TA, Almhanna K, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Esophageal and Esophagogastric Junction Cancers, version 1.2016. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician-gls/f-guidelines.asp#esophageal. Updated April 22, 2016. Accessed June 28, 2016.
16. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18-43.
17. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol LabMed. 2014;138:241-256.
18. Agency for Healthcare Research and Quality. Guidelines into decision support (GLIDES) (Connecticut). https://healthit.ahrq.gov/ahrq-funded-projects/guidelines-deci sion-support-glides. Accessed June 28, 2016.
19. Shiffman RN, Michel G, Rosenfeld RM, et al. Building better guidelines with BRIDGE-Wiz: development and evaluation of a software assistant to promote clarity, transparency, and implementability. J AmMed Inform Assoc. 2012;19:94-101.
20. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-926.
21. US Food and Drug Administration. Herceptin (trastuzumab) label information. http://www.accessdata.fda.gov/drug satfda-docs/label/2010/103792s5250lbl.pdf. Updated March 27, 2016. Accessed June 28, 2016.
22. Yoon HH, Shi Q, Sukov WR, et al. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol. 2012;30:3932-3938.
23. Wang S, Zheng G, Chen L, et al. Effect of HER-2/neu overexpression on prognosis in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 2011;12:1417-1423.
24. Xie SD, Xu CY, Shen JG, et al. HER 2/neu protein expression in gastric cancer is associated with poor survival [published correction appears in Mol Mod Rep. 2015;12 (3) :4794]. Mol Med Rep. 2009;2:943-946.
25. Aizawa M, Nagatsuma AK, Kitada K, et al. Evaluation of HER2-based biology in 1, 006 cases of gastric cancer in a Japanese population. Gastric Cancer. 2014;17:34-42.
26. Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cell Oncol. 2010;32:57-65.
27. Okines AF, Thompson LC, Cunningham D, et al. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol. 2013;24:1253-1261.
28. Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA international collaborative analysis. Ann Oncol. 2012;23:2656-2662.
29. Yoshida H, Yamamoto N, Taniguchi H, et al. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma. Virchows Arch. 2014;465:145-154.
30. Grillo F, Fassan M, Ceccaroli C, et al. The reliability of endoscopic biopsies in assessing HER2 status in gastric and gastroesophageal junction cancer: a study comparing biopsies with surgical samples. Transl Oncol. 2013;6:10-16.
31. Qiu Z, Sun W, Zhou C, et al. HER2 expression variability between primary gastric cancers and corresponding lymph node metastases. Hepatogastroenterology. 2015;62:231-233.
32. Selcukbiricik F, Erdamar S, Buyukunal E, et al. Is HER-2 status in the primary tumor correlated with matched lymph node metastases in patients with gastric cancer undergoing curative gastrectomy? Asian Pac J Cancer Prev. 2014;15:10607-10611.
33. Kochi M, Fujii M, Masuda S, et al. Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes. Diagn Pathol. 2013;8:191.
34. Fusco N, Rocco EG, Del Conte C, et al. HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. Mod Pathol. 2013;26:816-824.
35. Fassan M, Ludwig K, Pizzi M, et al. Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas. Hum Pathol. 2012;43:1206-1212.
36. Cho EY, Park K, Do I, et al. Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas. Mod Pathol. 2013;26:677-684.
37. Bozzetti C, Negri FV, Lagrasta CA, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer. 2011;104:1372-1376.
38. Saito T, Nakanishi H, Mochizuki Y, et al. Preferential HER2 expression in liver metastases and EGFR expression in peritoneal metastases in patients with advanced gastric cancer. Gastric Cancer. 2015;18:711-719.
39. Wong DD, de Boer WB, Platten MA, et al. HER2 testing in malignant effusions of metastatic gastric carcinoma: is it feasible? Diagn Cytopathol. 2015;43:80-85.
40. Jouret-Mourin A, Hoorens A, De Hertogh G, et al. Analysis of HER2 expression and gene amplification in adenocarcinoma of the stomach and the gastro-oesophageal junction: rationale for the Belgian way of working. Acta Gastroenterol Belg. 2012;75:9-13.
41. Gullo I, Grillo F, Molinaro L, et al. Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer. Endosc Int Open. 2015;3:E165-E170.
42. Ruschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25:637-650.
43. Satoh T, Bang YJ, Gotovkin EA, et al. Quality of life in the trastuzumab for gastric cancer trial. Oncologist. 2014;19:712-719.
44. Waddell T, Verheij M, Allum W, et al. Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl 6):vi57-vi63.
45. Ryu MH, Yoo C, Kim JG, et al. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur J Cancer. 2015;51:482-488.
46. Satoh T, Xu RH, Chung HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN- A randomized, phase III study. J Clin Oncol. 2014;32:2039-2049.
47. Hecht JR, Bang YJ, Qin SK, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC- A randomized phase III trial. J Clin Oncol. 2016;34:443-451.
48. Perez EA, Cortes J, Gonzalez-Angulo AM, et al. HER2 testing: current status and future directions. Cancer Treat Rev. 2014;40:276-284.
49. Ge X, Wang H, Zeng H, et al. Clinical significance of assessing Her2/neu expression in gastric cancer with dual tumor tissue paraffin blocks. Hum Pathol. 2015;46:850-857.
50. Koopman T, Louwen M, Hage M, et al. Pathologic diagnostics of HER2 positivity in gastroesophageal adenocarcinoma. Am J Clin Pathol. 2015;143:257-264.
51. Huang D, Lu N, Fan Q, et al. HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study. PLoS One. 2013;8:e80290.
52. Werner D, Battmann A, Steinmetz K, et al. The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing. J Transl Med. 2014;12:160.
53. Wang T, Hsieh ET, Henry P, et al. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status. Hum Pathol. 2014;45:970-975.
54. Cho J, Jeong J, Sung J, et al. A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages. Ann Surg Oncol. 2013;20(suppl 3):S477-S484.
55. Abrahao-Machado LF, Jacome AA, Wohnrath DR, et al. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays. World J Gastroenterol. 2013;19:6438-6446.
56. Radu OM, Foxwell T, Cieply K, et al. HER2 amplification in gastroesophageal adenocarcinoma: correlation of two antibodies using gastric cancer scoring criteria, H score, and digital image analysis with fluorescence in situ hybridization. Am J Clin Pathol. 2012;137:583-594.
57. Boers JE, Meeuwissen H, Methorst N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology. 2011;58:383-394.
58. Ruschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010;457:299-307.
59. Stanek L, Rozkos T, Laco J, et al. Comparison of immunohistochemistry, four in situ hybridization methods and quantitative polymerase chain reaction for the molecular diagnosis of HER2 status in gastric cancer: a study of 55 cases. Mol Med Rep. 2014;10:2669-2674.
60. Prins MJ, Ruurda JP, van Diest PJ, et al. Evaluation of the HER2 amplification status in oesophageal adenocarcinoma by conventional and automated FISH: a tissue microarray study. J Clin Pathol. 2014;67:26-32.
61. Grin A, Brezden-Masley C, Bauer S, Streutker CJ. HER2 in situ hybridization in gastric and gastroesophageal adenocarcinoma: comparison of automated dual ISH to FISH. Appl ImmunohistochemMol Morphol. 2013;21:561-566.
62. Kiyose S, Igarashi H, Nagura K, et al. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Pathol Int. 2012;62:728-734.
63. Fox SB, Kumarasinghe MP, Armes JE, et al. Gastric HER2 testing study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia. Am J Surg Pathol. 2012;36:577-582.
64. Yan B, Yau EX, Choo SN, et al. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples. J Clin Pathol. 2011;64:880-883.
65. Garcia-Garcia E, Gomez-Martin C, Angulo B, et al. Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence insitu hybridization with a novel fully automated dual-colour silver in-situ hybridization method. Histopathology. 2011;59:8-17.
66. Yan B, Yau EX, Bte Omar SS, et al. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol. 2010;63:839-842.
67. Kanayama K, Imai H, Yoneda M, et al. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: a comparative study among immunohistochemistry, FISH, and dual-color in situ hybridization. Cancer Sci. 2016;107:536-542.
68. Kataoka Y, Okabe H, Yoshizawa A, et al. HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer. 2013;16:84-93.
69. Clinical and Laboratory Standards Institute. Quality Assurance for Design Control and Implementation of Immunohistochemistry Assays; Approved Guideline. 2nd ed. CLSI document I/LA28-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.
70. Clinical and Laboratory Standards Institute. Fluorescence In Situ Hybridization Methods for Clinical Laboratories; Approved Guideline. 2nd ed. CLSI document MM07-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.
71. Fitzgibbons PL, Bradley LA, Fatheree LA, et al. Principles of analytic validation of immunohistochemical assays: guideline from the College of American Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med. 2014;138:1432-1443.
72. Jennings L, Van Deerlin VM, Gulley ML. Recommended principles and practices for validating clinical molecular pathology tests. Arch Pathol Lab Med. 2009;133:743-755.
73. College of American Pathologists. Accreditation checklists. http://www.cap.org/web/oracle/webcenter/portalapp/page hierarchy/accreditation-checklists.jspx?-afrLoop+962335452533098#!%40%40%3F-afrLoop%3D962335452533098%26-adf.ctrlstate%3D105o0uy7wa-94. Accessed June 28, 2016.
74. Wang YK, Chen Z, Yun T, et al. Human epidermal growth factor receptor 2 expression in mixed gastric carcinoma. World J Gastroenterol. 2015;21:4680-4687.
75. Stahl P, Seeschaaf C, Lebok P, et al. Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterol. 2015;15:7.
76. Gordon MA, Gundacker HM, Benedetti J, et al. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol. 2013;24:1754-1761.
77. Prins MJ, Ruurda JP, van Diest PJ, et al. The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study. Ann Oncol. 2013;24:1290-1297.
78. Bang YJ. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer. J Clin Gastroenterol. 2012;46:637-648.
79. Behrens HM, Warneke VS, Boger C, et al. Reproducibility of Her2/neu scoring in gastric cancer and assessment of the 10% cut-off rule. Cancer Med. 2015;4:235-244.
80. Feuchtinger A, Stiehler T, Jutting U, et al. Image analysis of immunohistochemistry is superior to visual scoring as shown for patient outcome of esophageal adenocarcinoma. Histochem Cell Biol. 2015;143:1-9.
81. Lee HE, Park KU, Yoo SB, et al. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer. 2013;49:1448-1457.
82. Kim MA, Lee HJ, Yang HK, et al. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology. 2011;59:822-831.
83. Park SR, Park YS, Ryu MH, et al. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: results of GASTric cancer HER2 reassessment study 1 (GASTHER1). Eur J Cancer. 2016;53:42-50.
84. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202-209.
85. Cruz-Reyes C, Gamboa-Dominguez A. HER2 amplification in gastric cancer is a rare event restricted to the intestinal phenotype. Int J Surg Pathol. 2013;21:240-246.
86. Shan L, Ying J, Lu N. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. Diag Pathol. 2013;8:76.
87. Kunz PL, Mojtahed A, Fisher GA, et al. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol. 2012;20:13-24.
88. Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol. 2009;40:769-777.
89. Cappellesso R, Fassan M, Hanspeter E, et al. HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases. Hum Pathol. 2015;46:665-672.
90. Gasljevic G, Lamovec J, Contreras JA, et al. HER2 in gastric cancer: an immunohistochemical study on tissue microarrays and the corresponding whole-tissue sections with a supplemental fish study. Pathol Oncol Res. 2013;19:855-865.
91. Park JS, Rha SY, Chung HC, et al. Clinicopathological features and prognostic significance of HER2 expression in gastric cancer. Oncology. 2015;88:147-156.
92. Bartley AN, Christ J, Fitzgibbons PL, et al. Template for reporting results of HER2 (ERBB2) biomarker testing of specimens from patients with adenocarcinoma of the stomach or esophagogastric junction. Arch Pathol Lab Med. 2015;139:618-620.
93. Lankshear S, Srigley J, McGowan T, et al. Standardized synoptic cancer pathology reports-so what and who cares: a population-based satisfaction survey of 970 pathologists, surgeons, and oncologists. Arch Pathol Lab Med. 2013;137:1599-1602.
94. Nakhleh RE. Quality in surgical pathology communication and reporting. Arch Pathol Lab Med. 2011;135:1394-1397.
95. Goldsmith JD, Siegal GP, Suster S, et al. Reporting guidelines for clinical laboratory reports in surgical pathology. Arch Pathol Lab Med. 2008;132:1608-1616.
96. Gulley ML, Braziel RM, Halling KC, et al. Clinical laboratory reports in molecular pathology. Arch Pathol Lab Med. 2007;131:852-863.
97. Brugmann A, Lelkaitis G, Nielsen S, et al. Testing HER2 in breast cancer: a comparative study on BRISH, FISH, and IHC. Appl Immunohistochem Mol Morphol. 2011;19:203-211.
98. Pala EE, Bayol U, Ozguzer A, et al. HER2 status in gastric cancer: a comparison of two novel in situ hybridization methods (IQ FISH and dual color SISH) and two immunohistochemistry methods (A0485 and HercepTestTM). Pathol Res Pract. 2013;209:548-554.
99. Kim MA, Jung JE, Lee HE, et al. In situ analysis of HER2 mRNA in gastric carcinoma: comparison with fluorescence in situ hybridization, dual-color silver in situ hybridization, and immunohistochemistry. Hum Pathol. 2013;44:487-494.
100. Yamashita-Kashima Y, Shu S, Yorozu K, et al. Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridization [published correction appears in Gastric Cancer. 2014;17 (4) :648]. Gastric Cancer. 2014;17:638-647.
101. Tajiri R, Ooi A, Fujimura T, et al. Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization. Hum Pathol. 2014;45:725-734.
102. Asioli S, Maletta F, Verdun di Cantogno L, et al. Approaching heterogeneity of human epidermal growth factor receptor 2 in surgical specimens of gastric cancer. Hum Pathol. 2012;43:2070-2079.
103. Yang J, Luo H, Li Y, et al. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochem Biophys. 2012;62:221-228.
104. Zhu Z, Wang J, Sun Z, et al. Flotillin2 expression correlates with HER2 levels and poor prognosis in gastric cancer. PLoS One. 2013;8:e62365.
105. Sheffield BS, Garratt J, Kalloger SE, et al. HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation. Arch Pathol Lab Med. 2014;138:1495-1502.
106. Kushima R, Kuwata T, Yao T, et al. Interpretation of HER2 tests in gastric cancer: confirmation of interobserver differences and validation of a QA/QC educational program. Virchows Arch. 2014;464:539-545.
107. Warneke VS, Behrens HM, Boger C, et al. Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol. 2013;24:725-733.
108. Kim KC, Koh YW, Chang HM, et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1, 414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol. 2011;18:2833-2840.
109. Choritz H, Busche G, Kreipe H; Study Group HER2 Monitor. Quality assessment of HER2 testing by monitoring of positivity rates. Virchows Arch. 2011;459:283-289.
110. Gulley ML. Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma. Exp Mol Med. 2015;47:e134.
111. Millson A, Suli A, Hartung L, et al. Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification. J Mol Diagn. 2003;5:184-190.
112. Kinugasa H, Nouso K, Tanaka T, et al. Droplet digital PCR measurement of HER2 in patients with gastric cancer. Br J Cancer. 2015;112:1652-1655.
113. Schmitt E, Vegran F, Chevrier S, et al. Transcriptional expression of 8 genes predicts pathological response to firstline docetaxel+trastuzumab-based neoadjuvant chemotherapy. BMC Cancer. 2015;15:169.
114. Wang T, Amemiya Y, Henry P, et al. Multiplex ligationdependent probe amplification can clarify HER2 status in gastric cancers with "polysomy 17." J Cancer. 2015;6:403-408.
115. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134:e48-e72.
116. Werner M, Chott A, Fabiano A, et al. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol. 2000;24:1016-1019.
117. Khoury T, Sait S, Hwang H, et al. Delay to formalin fixation effect on breast biomarkers. Mod Pathol. 2009;22:1457-1467.
118. Kinsella MD, Birdsong GG, Siddiqui MT, et al. Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: correlation of results to corresponding tissue block (needle core and excision) samples. Diagn Cytopathol. 2013;41:192-198.
119. Shabaik A, Lin G, Peterson M, et al. Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma. Diagn Cytopathol. 2011;39:328-332.
120. Kumar SK, Gupta N, Rajwanshi A, et al. Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma. Cytopathology. 2012;23:181-186.
121. Bueno Angela SP, Viero RM, Soares CT. Fine needle aspirate cell blocks are reliable for detection of hormone receptors and HER-2 by immunohistochemistry in breast carcinoma. Cytopathology. 2013;24:26-32.
122. Hanley KZ, Birdsong GG, Cohen C, et al. Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations. Cancer. 2009;117:279-288.
123. Pegolo E, Machin P, Riosa F, et al. Hormone receptor and human epidermal growth factor receptor 2 status evaluation on ThinPrep specimens from breast carcinoma: correlation with histologic sections determination. Cancer Cytopathol. 2012;120:196-205.
124. Sumiyoshi K, Shibayama Y, Akashi S, et al. Detection of human epidermal growth factor receptor 2 protein and gene in fine needle aspiration cytology specimens and tissue sections from invasive breast cancer: can cytology specimens take the place of tissue sections? Oncol Rep. 2006;15:803-808.
125. Beatty BG, Bryant R, Wang W, et al. HER-2/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis. Am J Clin Pathol. 2004;122:246-255.
126. Ferguson J, Chamberlain P, Cramer HM, et al. ER, PR, and Her2 immunocytochemistry on cell-transferred cytologic smears of primary and metastatic breast carcinomas: a comparison study with formalin-fixed cell blocks and surgical biopsies. Diagn Cytopathol. 2013;41:575-581.
127. Gruchy JR, Barnes PJ, Dakin Hache KA. CytoLyt (R) fixation and decalcification pretreatments alter antigenicity in normal tissues compared with standard formalin fixation. Appl Immunohistochem Mol Morphol. 2015;23:297-302.
128. Willmore-Payne C, Metzger K, Layfield LJ. Effects of fixative and fixation protocols on assessment of Her-2/neu oncogene amplification status by fluorescence in situ hybridization. Appl ImmunohistochemMol Morphol. 2007;15:84-87.
129. Babic A, Loftin IR, Stanislaw S, et al. The impact of preanalytical processing on staining quality for H&E, dual hapten, dual color in situ hybridization and fluorescent in situ hybridization assays. Methods. 2010;52:287-300.
130. Zhang Z, Yuan P, Guo H, et al. Assessment of hormone receptor and human epidermal growth factor receptor 2 status in breast carcinoma using Thin-Prep cytology fine needle aspiration cytology FISH experience from China. Medicine (Baltimore). 2015;94:e981.
131. Gertych A, Mohan S, Maclary S, et al. Effects of tissue decalcification on the quantification of breast cancer biomarkers by digital image analysis. Diagn Pathol. 2014;9:213.